Identifiants & Marche
Ticker
LUMO
ISIN
US55028X1090
CIK
0001126234
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
US
Siege
N/A
Fondee
N/A
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.